ARTICLES BY MATTHEW PILLAR

• Where Science Leads, Business Follows

  6/1/2023

  Learn how science, rather than market and investor expectations, directed Francois Rieger’s oversight of the Medsenic/Bone Therapeutics merger.

• The Hybrid Face Of Biopharma

  5/1/2023

  What came first, the development platform or the therapeutic asset? To a growing class of biotechs, it doesn’t even matter.

• Tech-Heavy Drug Discovery Yields Deep Pipeline

  4/3/2023

  The Business of Biotech caught up with Recursion Co-Founder & CEO Chris Gibson, Ph.D. on the heels of the company launching four clinical trials in just three quarters. That progress was built on a foundation of rapid, machine-enabled drug discovery.

• Why RNA Is Good For Business

  3/1/2023

  RNA’s not just good science, it’s good for business. No one understands this better than Nutcracker Therapeutics’ Dr. Geoff Nosrati, whose Ph.D. in Biochemistry and Molecular Biology supports him in his current role as Chief Business Officer at Nutcracker Therapeutics.

• Where Oncology Treatment Goes Next

  2/1/2023

  Dr. Steve Davidsen’s long tenure leading drug discovery efforts at AbbVie offers rare perspective into how far oncology treatment has come, and what’s needed to continue its progress.

• Anatomy Of A Biopharma VC Deal

  1/3/2023

  Ray Therapeutics CEO Paul Bresge and 4BIO Capital Managing Partner Dmitri Kuzmin, Ph.D. break down the deal that launched Ray and ponder the risk of a mission-driven biopharma CEO.

• The Rise Of Computational Biology In Biopharma

  12/1/2022

  I thought I’d peel a layer off the onion to reveal a trend that’s gaining momentum and having a positive impact during a somewhat negative biopharma news cycle: computational biology.

• Cashing In On Collaboration

  11/1/2022

  Our conversation with Philogen CEO, CSO, and Cofounder Prof. Dario Neri reveals his company’s metered emergence from academia, its avoidance of venture capital, and its rapid realization of revenue through pre-pipeline collaboration.

• What’s True Of Mice ≠ What’s True Of Men

  10/3/2022

  As ATMPs advance, scientists are calling out the limited value of mouse models in pharmacological research and testing. LIfT Biosciences’ Founder and CEO Alex Blyth is a vocal proponent of organoid/tumoroid models.

• The “Liberation” Of Science Yields A New Class Of Biopharma Leadership

  9/1/2022

  Purespring Therapeutics’ Richard Francis is among the dozens of Big Pharma executives who have defected to biopharma startups by riding the science, technology, and finance tides.

• Venture Philanthropy Launches Biotech From Within

  8/1/2022

  A summary of a discussion with Ben Yerxa, CEO of Opus Genetics, an early-stage gene therapy company launched in 2021 and in unique fashion on the back of the patient advocacy group the Retinal Degeneration Fund.

• Formulation Alternatives: Looking Beyond Parenteral Biologics

  12/1/2021

  2022 could be a breakout year for oral, intranasal, and inhalable biologics. As innovative biopharma companies clear formulation, stability, and efficacy hurdles, market forecasts are rising fast.

• Democratizing Biologics With Lumen Bioscience's Brian Finrow, J.D. & Craig Behnke, Ph.D.

  11/28/2021

  Lumen Bioscience's cofounder and CEO, Brian Finrow, J.D., and EVP of production/development, Craig Behnke, Ph.D., discuss the development of therapeutic proteins from readily available food algae spirulina. It's driving a diverse pipeline of candidates into the clinic, for indications reaching from the gut to the heart and lungs.

• Beat The Breakthrough Therapy Designation Dearth

  11/1/2021

  Historically, winning FDA BTD (Breakthrough Therapy designation) translated to 50/50 odds of full agency approval, but this harbinger of candidate commercialization has hit a dry spell.

• Competitive Differentiation In A Crowded Market

  10/12/2021

  When is it time for an emerging biopharma company to truly emerge, and what goes into its competitive positioning? Biopharma industry veteran Allan Shaw shares insight into developing a differentiation strategy on an increasingly crowded, and evermore complex playing field.